**Background**
Olanzapine is a widely utilized atypical antipsychotic medication primarily prescribed for the treatment of schizophrenia and bipolar disorder. The pharmacological efficacy and safety profile of olanzapine are heavily influenced by its metabolic pathways and stability. Understanding the metabolites and degradation products of this compound is critical for pharmacokinetic studies, drug safety assessments, and forensic toxicology. Specifically, the identification of metabolites allows researchers to determine how the drug is processed in the body and how it may break down under various environmental conditions. In this context, we will introduce a key metabolite and degradation product – 2-Hydroxymethyl olanzapine.
**Definition**
2-Hydroxymethyl olanzapine is a metabolite and a degradation product of olanzapine, characterized by the molecular formula C17H20N4OS and a molecular weight of 328.43.
**Experimental Studies**
The 2-Hydroxymethyl olanzapine description identifies it as a significant derivative of the parent drug olanzapine. According to 2-Hydroxymethyl olanzapine technical information, this compound has been identified both as a product of biological metabolism and as a result of chemical degradation. In pharmacokinetic studies, reversed-phase HPLC with electrochemical detection was employed to analyze the presence of olanzapine and its metabolites in rat plasma, confirming the biological origin of this compound. Furthermore, forensic research has successfully identified 2-hydroxymethyl-olanzapine as a novel degradation product, which is essential for the accurate interpretation of post-mortem drug concentrations and stability testing. While specific IC50 values are not typically associated with this metabolite, its presence serves as a critical marker for olanzapine metabolism and degradation. In conclusion, 2-Hydroxymethyl olanzapine is a vital reference standard for pharmaceutical analysis and pharmacokinetic research.
Keywords
2-Hydroxymethyl olanzapine, 174756-45-7, LY-290411, 2-OH-OLZ, LY290411, LY 290411, Drug Metabolite, Olanzapine, Inhibitor, inhibitor, inhibit
References
[1] Chiu JA, et al. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J Pharm Biomed Anal. 1996 Mar;14(5):609-615.
[2] Saar E, et al. Identification of 2-hydroxymethyl-olanzapine as a novel degradation product of olanzapine. Forensic Sci Int. 2012 Jul 10;220(1-3):74-9.